Edition:
United Kingdom

Deena Beasley

Trump signs order aimed at development of better flu vaccines

19 Sep 2019

U.S. President Donald Trump on Thursday signed an executive order aimed at spurring the development of better vaccines to protect against seasonal influenza as well as a potential pandemic flu outbreak.

Amgen drug shrinks lung cancer tumors in half of patients: study

08 Sep 2019

An experimental Amgen Inc drug that targets a specific genetic mutation reduced tumor size in around half of advanced lung cancer patients given the highest dose in a small, early-stage trial, the company said on Sunday.

Amgen wins U.S. patent battle on arthritis drug Enbrel, thwarting Novartis

10 Aug 2019

A U.S. judge on Friday upheld two patents relating to Amgen Inc's blockbuster rheumatoid arthritis drug Enbrel, denying a challenge by Novartis AG, which is seeking to launch a copycat version.

Medicare to cover expensive cancer cell therapies

07 Aug 2019

The U.S. Centers for Medicare and Medicaid Services (CMS) on Wednesday said it has finalized a decision to cover expensive cancer cell therapies sold by Gilead Sciences Inc and Novartis AG .

Patient groups push back against Gilead's pricey HIV prevention treatment

07 Aug 2019

LOS ANGELES Gilead Sciences Inc hopes to soon introduce a pricey new pill to prevent HIV in people at risk of contracting the infection, but the drugmaker faces opposition from an unusual source: patient advocates.

Amgen results beat estimates, lung cancer trial planned

31 Jul 2019

Amgen Inc on Tuesday said its second-quarter revenue fell 3% due to more competition for its older off-patent drugs, but rising sales of newer medicines helped its results exceed Wall Street forecasts.

Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments

30 Jul 2019

LOS ANGELES Unusually high numbers of U.S. lymphoma patients are choosing experimental treatments over expensive cell therapies sold by Gilead Sciences Inc and Novartis AG , new data shows, helping explain why sales of the two products have not met rosy expectations.

Amgen quarterly revenue dips 3% but profit tops Street expectations

30 Jul 2019

July 30 Amgen Inc on Tuesday said its second-quarter revenue fell 3% due to more competition for its older off-patent drugs, but rising sales of newer medicines helped the company's results exceed Wall Street estimates.

World News